• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Warby Parker Inc. filed SEC Form 8-K: Leadership Update

    10/4/24 5:00:14 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email
    false 0001504776 0001504776 2024-10-01 2024-10-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): October 1, 2024

     

    Warby Parker Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction

    of Incorporation)

    001-40825

    (Commission

    File Number)

    80-0423634

    (IRS Employer

    Identification No.)

     

    233 Spring Street, 6th Floor East

    New York, New York

    10013

    (Address of Principal Executive Offices) (Zip Code)

     

    (646) 847-7215

    (Registrant's Telephone Number, Including Area Code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

      Name of each exchange on which
    registered
    Class A Common Stock, $0.0001 par value   WRBY   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (P30.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On October 1, 2024, Gabrielle Sulzberger notified the board of directors (the “Board”) of Warby Parker Inc. (the “Company”) of her intention to resign as a member of the Board, effective on October 18, 2024 (the “Resignation Effective Time”). Ms. Sulzberger’s resignation is a result of her desire to focus on her other personal and professional commitments and not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

     

    On October 4, 2024, the Board approved a decrease in the size of the Board from ten (10) directors to nine (9) directors in accordance with the Company’s Amended and Restated Bylaws and Restated Certificate of Incorporation, effective upon the Resignation Effective Time. On the same date, in order to achieve an equal balance of membership among the Board’s three classes of directors, the Board determined that Teresa Briggs should be reclassified from Class I, with a term expiring at the Company’s 2025 Annual Meeting of Stockholders, to Class III, with a term expiring at the Company’s 2027 Annual Meeting of Stockholders. Accordingly, and solely to effect such change, effective upon the Resignation Effective Time, Ms. Briggs resigned as a Class I director and was immediately elected by the Board as a Class III director, effective as of the Resignation Effective Time. The resignation and re-election of Ms. Briggs was effected solely to rebalance the Board’s classes, and for all other purposes, including committee service and compensation, Ms. Briggs’s service on the Board is deemed to have continued uninterrupted.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      WARBY PARKER INC.
       
    Dated: October 4, 2024 By: /s/ Chris Utecht
        Chris Utecht
        SVP, General Counsel & Secretary

     

     

     

    Get the next $WRBY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    12/10/2025$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    11/7/2025$28.00 → $24.00Outperform
    Telsey Advisory Group
    8/1/2025$22.00 → $28.00Outperform
    Telsey Advisory Group
    7/10/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    More analyst ratings

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    8/14/24 4:52:02 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    SEC Filings

    View All

    Warby Parker Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Warby Parker Inc. (0001504776) (Filer)

    2/9/26 4:19:28 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Warby Parker Inc.

    SCHEDULE 13G/A - Warby Parker Inc. (0001504776) (Subject)

    1/23/26 11:08:18 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    SEC Form 144 filed by Warby Parker Inc.

    144 - Warby Parker Inc. (0001504776) (Subject)

    1/13/26 4:21:45 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Warby Parker upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Warby Parker from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    12/10/25 9:45:30 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $24.00 from $28.00 previously

    11/7/25 7:48:31 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

    Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $28.00 from $22.00 previously

    8/1/25 8:16:04 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Mitchell Adrian V

    4 - Warby Parker Inc. (0001504776) (Issuer)

    2/12/26 7:01:12 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Mitchell Adrian V

    3 - Warby Parker Inc. (0001504776) (Issuer)

    2/12/26 6:59:22 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Co-Chief Executive Officer Blumenthal Neil Harris sold $19,793 worth of shares (660 units at $29.99) and converted options into 660 shares (SEC Form 4)

    4 - Warby Parker Inc. (0001504776) (Issuer)

    1/15/26 6:36:33 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Warby Parker to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 will be released before market open on February 26, 2026. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 275034. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.c

    2/12/26 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Appoints Adrian Mitchell as Chief Financial Officer

    Warby Parker Inc. (NYSE:WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment strengthens Warby Parker's leadership team as the company continues executing its strategic vision, building on a track record of retail and product innovation while expanding into new categories, including the launch of its first AI glasses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209259218/en/Adrian Mitchell, Chief Financial Officer Mitchell has more than 25 years of experience leading some of the worl

    2/9/26 4:10:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

    Warby Parker Inc. (NYSE: WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that the Company will be presenting at the Morgan Stanley Global Consumer & Retail Conference on Tuesday, December 2, 2025 at 3:00 p.m. Eastern Time. The presentation will be webcast live over the internet and can be accessed at https://investors.warbyparker.com. An online archive will be available for a period of 90 days following the presentation. About Warby Parker Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style–without charging a premium for it. Headquartered in New York City, the co-

    11/26/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Leadership Updates

    Live Leadership Updates

    View All

    Warby Parker Appoints Adrian Mitchell as Chief Financial Officer

    Warby Parker Inc. (NYSE:WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment strengthens Warby Parker's leadership team as the company continues executing its strategic vision, building on a track record of retail and product innovation while expanding into new categories, including the launch of its first AI glasses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209259218/en/Adrian Mitchell, Chief Financial Officer Mitchell has more than 25 years of experience leading some of the worl

    2/9/26 4:10:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Monumental Sports & Entertainment Appoints Corporate Finance Executive Steven Miller as Executive Vice President and Chief Financial Officer

    Steven Miller, currently Chief Financial Officer and Treasurer of Warby Parker (NYSE: WRBY), has been appointed Chief Financial Officer of Monumental Sports & Entertainment, effective October 2, 2025, and will join the Senior Executive Leadership TeamAs previously announced, after an extraordinary 25-year career at Monumental Sports & Entertainment, Peter Biché transitioned from Chief Financial Officer to Senior Advisor WASHINGTON, Sept. 9, 2025 /PRNewswire/ -- Monumental Sports & Entertainment (MSE), one of the nation's leading integrated sports, media, and entertainment companies, announced that Steven (Steve) Miller will become its Executive Vice President and Chief Financial Officer (CFO

    9/9/25 6:30:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

    Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

    8/1/24 4:15:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Financials

    Live finance-specific insights

    View All

    Warby Parker to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the fourth quarter and year ended December 31, 2025 will be released before market open on February 26, 2026. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 275034. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.c

    2/12/26 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker Announces Third Quarter 2025 Results

    Net revenue growth accelerated to 15% year over year Active Customers growth accelerated to 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the third quarter ended September 30, 2025. "This was a strong quarter for our team as we advanced our strategic priorities and accelerated both topline and customer growth. As we step into Warby Parker's next act, one defined by innovation through AI, we're energized to create new products like AI glasses, enhance the customer experience and drive productivity," shared Co-Founder and Co-CEO Neil Blume

    11/6/25 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Warby Parker to Announce Third Quarter 2025 Financial Results November 6, 2025

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2025 will be released before market open on November 6, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 646-844-6383 from international locations. The conference passcode is 958403. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where p

    10/16/25 7:00:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 5:08:23 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/14/24 1:30:16 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

    SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

    11/12/24 10:40:28 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care